- 7/24 Live Call Center
Stem cells can develop into many cell types and act as the body’s repair system. They replace or restore damaged tissues, offering new possibilities for treating diseases.
Send us all your questions or requests, and our expert team will assist you.
The term “Myelodysplastic Syndromes” is plural for a reason. It is not a single disease but a collection of related disorders that share standard features but behave differently. The specific condition a patient has is determined by examining the blood and bone marrow cells under a microscope and analyzing their chromosomes. Understanding the particular subtype is the critical first step in determining the treatment indication. The World Health Organization (WHO) classification system is the standard used by pathologists to categorize these conditions.
Heterogeneity means the clinical course can vary widely. One patient might have a very mild form of MDS that requires no treatment other than occasional monitoring and can live a normal lifespan. Another patient might have a highly aggressive form that mimics acute leukemia and requires urgent intervention with stem cell transplantation. This variability is why accurate classification and risk stratification are paramount.
The classification is based on which blood lines are involved (red cells, white cells, or platelets), the look of the cells (dysplasia), the presence of ring sideroblasts (iron-loaded mitochondria), and the percentage of blasts (immature cells).
MDS with Isolated del(5q): This is a distinct genetic entity where the long arm of chromosome 5 is missing. It is more common in women and is characterized by severe anemia, but often a preserved platelet count. It has a specific therapy indication (lenalidomide) and a generally favorable prognosis.
The symptoms of MDS are the direct result of the bone marrow’s inability to produce functional blood cells. The “indication” for medical investigation usually arises from an abnormal blood test or the onset of symptoms related to cytopenias (low blood cell counts).
Thrombocytopenia (Low Platelets): Platelets are required for clotting. Indications include easy bruising, petechiae (tiny red dots on the skin), prolonged bleeding from minor cuts, nosebleeds (epistaxis), or bleeding gums.
A significant part of the condition’s profile is its potential to evolve. MDS is a dynamic disease. The indication for early intervention, such as a stem cell transplant, often depends on the “risk” of the disease progressing to AML.
This is a specific and particularly challenging condition. It occurs as a late complication of cytotoxic chemotherapy or radiation therapy given for a previous cancer. For example, a patient treated for breast cancer or lymphoma may develop MDS 5 to 7 years later.
The decision to pursue regenerative therapy (Stem Cell Transplant) is a complex calculation. It is not indicated for everyone.
Age and Fitness: Historically, a transplant was reserved for young patients. However, with “reduced intensity” conditioning regimens, fit patients up to age 70 or 75 are now considered for this regenerative option at specialized centers.
Send us all your questions or requests, and our expert team will assist you.
Blasts are immature blood cells that should usually make up less than 5 percent of the cells in the bone marrow. When they are present in higher numbers (5-19%), it is called “excess blasts.” This signifies that the MDS is more aggressive and has a higher likelihood of transforming into acute leukemia.
The deletion of the long arm of chromosome 5 (del 5q) creates a unique subtype of MDS. These patients often have severe anemia but normal or high platelet counts. Crucially, this specific genetic change makes the disease highly responsive to a particular drug, lenalidomide, which usually eliminates the need for blood transfusions.
MDS specifically progresses to Acute Myeloid Leukemia (AML). It does not typically transform into solid tumors (like lung or breast cancer) or lymphoid cancers (like lymphoma). However, because MDS is often a disease of DNA damage, patients may have an inherent susceptibility to other cancers independent of the MDS progression.
Petechiae are pinpoint, round spots on the skin caused by bleeding. The bleeding causes the petechiae to appear red, brown, or purple. In MDS, they are a common sign of thrombocytopenia (low platelet count) and usually appear on the lower legs or ankles.
No. Iron-deficiency anemia is caused by a lack of the raw material (iron) needed to make hemoglobin. MDS anemia is caused by a broken factory (bone marrow) that cannot produce red blood cells properly, even if there is plenty of iron. In fact, MDS patients often have too much iron due to transfusions.
Multiple sclerosis (MS) is a disease that harms the brain’s control over the body. It has four main types: Relapsing-remitting MS (RRMS), Primary-progressive MS (PPMS),
Your Comparison List (you must select at least 2 packages)
